Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:9254
Name mast-cell leukemia
Definition A leukemia that results_in an overwhelming number of tissue mast cells located_in peripheral blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia mast-cell leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
KIT V560G KIT D816V Dasatinib mast-cell leukemia sensitive detail...
KIT V560G KIT D816V Ponatinib mast-cell leukemia sensitive detail...
KIT V560G KIT D816V BPR1J373 mast-cell leukemia sensitive detail...
KIT S476I Midostaurin mast-cell leukemia predicted - sensitive detail...
KIT S476I Nilotinib mast-cell leukemia predicted - sensitive detail...
KIT V560G KIT D816V Avapritinib mast-cell leukemia sensitive detail...
KIT V560G Avapritinib mast-cell leukemia sensitive detail...
Unknown unknown Midostaurin mast-cell leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02415608 Phase II Ibrutinib Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Terminated
NCT03214666 Phase Ib/II GTB-3550 TriKE GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies Recruiting
NCT03580655 Phase II Avapritinib (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Recruiting